August 28, 2024 02:41 PM EDT
Pharma
Law

Delaware high court to re­view ex­pert tes­ti­mo­ny in Zan­tac suits, in win for drug­mak­ers

Nicole DeFeudis

Editor

Ten of the plain­tiff-cho­sen ex­perts ex­pect­ed to tes­ti­fy in lit­i­ga­tion over whether the heart­burn drug Zan­tac caused can­cer will be re­viewed by the Delaware Supreme …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times